Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Markers for judging curative effect of clinical treatment on membranous nephropathy

A technique for membranous nephropathy and clinical treatment, applied in the field of markers for judging the efficacy of clinical treatment on membranous nephropathy

Pending Publication Date: 2020-02-04
THE FIRST PEOPLES HOSPITAL OF FOSHAN
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patented technology predicts how many times someone has sickened their kidney by taking certain drugs called tacrolimus or other substances from another person's body. They found out they had better ways to treat these diseases before getting them back into normal blood circulation. By measuring changes made during testing over time, researchers could determine which medications were effective against those who are already affected.

Problems solved by technology

Technics Problem addressed in this patents relate to identifying and removing cancer from tissues called glioma through an intrinsic mechanism involving both innately distributed and unique parts within each individual brain area. Current treatments like chemo therapeutic agents targeting either single proteins or small groups of DNA involved in signal transduction processes, while current techniques involve modifying these structures outside their original structure.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Markers for judging curative effect of clinical treatment on membranous nephropathy
  • Markers for judging curative effect of clinical treatment on membranous nephropathy
  • Markers for judging curative effect of clinical treatment on membranous nephropathy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] Validation was performed in 19 patients with membranous nephropathy. Peripheral blood was collected from each patient, RNA was extracted, 5'RACE was reverse transcribed, and PCR amplification was performed with primers consisting of the outer primer of the β chain: 5'-AGATCTCTGCTTCTGATGGCT-3' and the inner primer of the β chain: 5'-TGGCTCAAACACAGCGACCT-3' The TCR library of the samples is then sequenced using a second-generation sequencing platform.

[0020] According to the sequencing data, the sequence alignment tool blat is called through the perl programming language to perform sequence alignment between the kernel and the reference sequence. Based on the reference coordinates of the TCR gene, the alignment results are annotated, and the output contains various indicators recognized in the current TCR library analysis. , so as to obtain the usage frequency of V gene of each sample by bioinformatics analysis. According to the use frequency of TCR Vβ13 gene, 8 of the...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses markers for judging the curative effect of clinical treatment on membranous nephropathy. The group of markers includes TCR V beta 13, specifically, when the total use frequencyof a V gene in a sample is counted, if the percentage of the use frequency of the TCR V beta 13 is greater than 0.046%, it is predicted that the clinical treatment has a curative effect on membranousnephropathy. The TCR V beta 13 in a TCR coding gene of a patient is taken as a marker, if the use frequency of TCR V beta 13 is greater than 0.046%, it can be predicted that the clinical treatment has the curative effect on the patient with membranous nephropathy, it is predicted that after the clinical treatment, a qualitative experiment of urine protein shows a negative result, the AUC of thismethod is 0.80, when a threshold is set to 0.046%, sensitivity is 0.75, and specificity is 0.728.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Owner THE FIRST PEOPLES HOSPITAL OF FOSHAN
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com